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One salient feature of randomized clinical trials is that patients are randomly allocated to treatment groups, but not
randomly sampled from any target population. Without random sampling parametric analyses are inexact, yet they are
still often used in clinical trials. Given the availability of an exact test, it would still be conceivable to argue convinc
ingly that for technical reasons (upon which we elaborate) a parametric test might be preferable in some situations.
Having acknowledged this possibility, we point out that such an argument cannot be convincing without supporting
facts concerning the specifics of the problem at hand. Moreover, we have never seen these arguments made in practice.
We conclude that the frequent preference for parametric analyses over exact analyses is without merit. In this article we
briefly present the scientific basis for preferring exact tests, and refer the interested reader to the vast literature backing
up these claims. We also refute the assertions offered in some recent publications promoting parametric analyses as
being superior in some general sense to exact analyses. In asking the reader to keep an open mind to our arguments, we
are suggesting the possibility that numerous researchers have published incorrect advice, which has then been taught
extensively in schools. We ask the reader to consider the relative merits of the arguments, but not the frequency with
which each argument is made.
Keywords: Exactness, Nonparametric, Permutation test, Reality-based analyses, Robustness, Validity
Introduction
Medical errors may be classified by the broken link in the
chain connecting (a) study objectives to (b) medical data
bases to (c) p-values to (d) study conclusions to (e) recom
mendations to (f) accepted medical practice to (g) actual
medical practice. Medical errors attributable to physicians
deviating from accepted practice, corresponding to the last
link in the chain, (f) to (g), may attract the most malprac
tice suits and media attention. Yet the frequent insidious
errors that occur at the second link, from (b) to (c), involv
ing inappropriate statistical methodology, may result in
even more damage (Bailar, 1976). In some cases, assump
tions are required to calculate p-values, but when a plati
num standard analysis is available so that “significance
[may be] assessed in a way not involving unverifiable
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assumptions” (Tukey, 1993), it would be a (b) to (c) error
not to use it.
In randomized clinical trials (RCTs), the random
allocation of patients to treatment groups serves as the basis
for valid between-group inference. In RCTs, then, neither
random sampling from a target population nor unverifi
able assumptions are required (Feinstein, 1993) to con
struct between-group tests that allow Type I errors (false
positive findings) to occur at no greater than a specified
rate ( a ). These platinum standard tests are design-based
permutation tests that use as the reference distribution the
set of actual potential allocation sequences (Berger, 2000a,
Section 3.1). We will refer to design-based platinum stan
dard permutation tests as exact in the remainder of the ar
ticle, yet two caveats are needed to qualify the use of the
word “exact” in this context.
First, design-based tests are exact for the strong
null hypothesis, which specifies that each patient would
respond identically to each treatment under study. This
strong null hypothesis is not the complement of the superi
ority alternative hypothesis. There is an indifference re
gion in which the weak null hypothesis (specifying com
mon population response rates or means) is true but the
strong null hypothesis is not. Design-based tests need not
be exact on this region.
Second, exactness is not preserved, even for the
strong null hypothesis, when the analysis is based on a
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randomization scheme other than the one that was actually parametric tests be used in RCTs. For example, Barber
used. Software may not always be available for construct and Thompson (2000) criticized the use of the exact
ing a test that mimics the actual randomization used. The Wilcoxon-Mann-Whitney (WMW) test instead of the para
size of the study may preclude the possibility of enumerat metric t-test in a RCT. Likewise, Shuster (1990) and Hewett
ing all possible permutations of treatment allocations con et al. (2000) were both critical of Fisher’s exact test for
sistent with the actual randomization used, and Monte Carlo binary data.
We return to these articles after illustrating the
approximations may be needed. So not every permutation
test that is called exact is design-based, and it is not clear discrepancy between the nominal a level and the actual
that permutation tests which are not design-based are more a level. In arguing the obvious point that the actual level
robust than parametric tests. Even design-based permuta ought not exceed the nominal level (whether or not it is
tion tests, which are necessarily more robust (in the sense 0.05) we refute the application of Agresti and Coull’s (1998)
of keeping the power under a ) than parametric tests when assertions to hypothesis testing in RCTs. We specialize
the strong null hypothesis is true, may not be more robust this argument to the case of continuous data, using as an
than parametric tests when the weak null hypothesis is true example a recent RCT to compare open access to routine
and the strong null hypothesis is not. Although technically appointments for inflammatory bowel disease (Williams
this opens the door to the possibility that in some cases the et al., 2000a). We pay particular attention to the points
parametric test may be preferable to the best available per made by Barber and Thompson (2000), and refute the key
mutation test, none of us can recall this argument being one about the relative merits of the t-test and the WMW
used in practice to justify a parametric analysis. Without a test. We specialize to the comparison between the Chidetailed investigation of the robustness of each test in the squared test and Fisher’s exact test for binary data, using
specific situation, we would consider the best way to de as an example a recent study of the effect of neuromuscu
cide between a parametric test and a permutation test to be lar training on knee injuries in female athletes (Hewett et
the conditions for its exactness.
al., 1999). Here we refute the points made by Shuster
A parametric test requires both random sampling (1990) and Hewett et al. (2000). Then, we discuss and
and proper specification of the distribution from which one refute some of the reasons often cited for using a paramet
is sampling randomly to be exact. In some sense, a differ ric test instead of an exact one. Finally, we provide rec
ent random allocation scheme, which is all that is needed ommendations.
for non-design-based permutation tests to be exact, comes
closer to the actual random allocation scheme than ran Strict Preservation of the Type I Error Rate ( a )
dom sampling from a known distribution does. In addi
As the probability of a false positive, the Type I
tion, inexactness caused by the use of Monte Carlo sam error rate ( a ) has been called the regulator’s risk in the
pling can be bounded by selection of the number of points drug evaluation context. This may suggest that only regu
in the sample space.
lators need to concern themselves with the frequency, un
For these reasons, we consider only cases in which der null conditions (i.e., an ineffective medical interven
the permutation test (even if not design-based) can safely tion), with which analyses claim statistical significance (i.e.,
be presumed to be more robust than the parametric test, superior efficacy). This is a dangerous view, because even
and we note that this covers every case we have encoun a medical error attributable to a break in the second link of
tered in practice. The disturbing overuse of parametric the chain, (b) to (c), is still a medical error that can cause
analyses in these cases cannot be explained by the lag time tremendous damage (Bailar, 1976). The “only assurance
required for new methods to gain acceptance in practice of the low likelihood of [the approval of ineffective com
(Altman & Goodman, 1994) - in fact permutation tests are pounds that have serious adverse effects] is the Type I er
not new (Ludbrook & Dudley, 1998, Section 4.1). More ror” which must “occur at tolerably low rates [for] the com
likely, this trend is due to a combination of the reluctance munity [to] best be assured that the conclusions of the trial
of journal editors to accept correctness in place of prece most likely reflect the anticipated experience of patients”
dent (Ludbrook & Dudley, 1998) and some recent publi (Moye, 1999, bracketed material added for clarity).
cations that endorse parametric analyses.
In this section, we take a careful look at the ac
For example, Agresti and Coull (1998) cited the tual a level, and distinguish it from the tolerably low rate,
conservatism of exact methods as a reason to use approxi which is (or should be) the nominal a level. In this dis
mate methods. Because their article was not especially cussion we must bear in mind the added importance of the
focused on hypothesis testing or on RCTs, it does not strike Type I error rate due to the frequent unquestioning accep
us as entirely inconsistent with our views, although we do tance of positive between-group results (Berger, 2000a,
find it inappropriate to cite their article to justify the use of Section 1; Voutilainen, 2001). We note that allowing the
parametric tests in RCTs.
nominal a level to vary with the nature of the disease and
Other articles have specifically proposed that the safety profile of the agent under study may be quite
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reasonable. In no way do we insist that 0.05 should OND. This declaration will be made if the p-value is as
always be used for a . We do, however, insist that there low as or lower than the nominal a level, so the nominal
a level determines the number of ODC responses required
be adherence to whatever a level is selected.
Berger (2000a, Section 3.1) demonstrated the by each test to claim significant superiority of ODC. If we
potential for a parametric test to violate this basic tenet, pick a nominal a level of 0.0250, then the rejection re
and yet cover it up by calculating the a level incorrectly. gion consists of those outcomes for which the p-value is
This occurs because a parametric test is exact as an answer no greater than 0.0250. It turns out that both tests would
to one question, yet it is used for a different question. As have the same rejection region, consisting of the outcomes
an illustration, consider Table 14.2 in Section 14.2.6 of for which ODC has 19 or more responses. But this event
Berger and Ivanova (2001), based on the 2x2 contingency occurs with probability 0.0049, and not 0.0250. For this
table {(12,10);(3,19)} originally presented by Fox et al. nominal a level both tests are conservative (and equally
(1993). Columns are response outcomes (no or yes) and conservative). The outcome of ODC having 18 responses
rows are treatments, ondansetron (OND) vs. combination has a chi-square p-value o f0.0282 and a Fisher p-value of
therapy (ODC). The chi-square p-values are exact as an 0.0273, so it does not qualify for inclusion in either 0.0250
swers to the question “If one were to sample randomly rejection region (its p-value is too large). But if we change
from a chi-square distribution (with one degree of free the nominal a level from 0.0250 to 0.0275, then Fisher’s
dom), then what is the probability of finding results as ex exact test could fit the additional outcome into its rejec
tion region, while the chi-square test could not. Because
treme or more extreme than those we observed?”.
Had the' experiment actually employed random the chi-square rejection region still has null probability
sampling from a distribution that actually had a chi-square 0.0049, it still has the same actual a level, 0.0049. But
distribution, then this question would be equivalent to “If Fisher’s exact test now has a larger rejection region, with
one were to repeat the experiment performed, under null null probability 0.0273, which serves as its actual a level.
conditions (the equivalence of OND and ODC), then what In this case, Fisher’s exact test is much less conservative
is the probability of finding results as extreme or more than the chi-square test. This information appears in the
extreme than those we observed?”. In fact there was no table below.
random sampling, the population does not have a chi-square
With a nominal a level of0.0500, each test could
distribution, and the exact answer to the former question is include the 18 outcome but not the 17 outcome in its rej ecnot an exact answer to the latter question. To obtain an tion region, because p(17)=0.1014>0.05 and
exact answer to the latter question, which is the one of p(17)=0.1017>0.05, respectively, for Fisher’s exact test and
interest, we hypothetically repeat the experiment. This the chi-square test. Again, both tests are equally conserva
means re-randomizing the allocation repeatedly, using the tive. With a nominal a level of 0.2625 the tests again
same randomness (probability structure) that was used to diverge, with Fisher’s exact test rejecting for 17 but not 16
determine the actual allocation. Under the strong null hy (p=0.2628), while the chi-square test can reject for both
pothesis of no treatment effect the responses are indepen (p=0.2624 for 16), but not for 15 (p=0.5000). With an
dent of the allocation, so the responses do not change. This actual a level of 0.1014, Fisher’s exact test is quite con
allows us to compute the test statistic for each of these servative; but the chi-square test, with its actual a level of
hypothetical repeats of the experiment. This is how plati 0.2628, is anti-conservative. We have seen three distinct
num standard permutation tests ensure exactness.
cases, but we did not see a case in which the chi-square
The one-sided actual a level is the probability, test was simultaneously valid and less conservative than
under the null hypothesis (OND and ODC being equally Fisher’s exact test. Because the Fisher actual a-level will
effective), of declaring that ODC is more effective than
Table 1. Fisher’s Exact Test Vs Chi-Square Test
Nominal a
(one-sided)

Fisher’s exact test
cut-off actual a

Chi-square test
cut-off actual a

Compared to Fisher’s exact
test the chi-square test is

0.0250

19

0.0049

19

0.0049

equally conservative

0.0275

18

0.0273

19

0.0049

more conservative

0.0500

18

0.0273

18

0.0273

equally conservative

0.2625

17

0.1014

16

0.2628

anti-conservative
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be that attainable p-value closest to but not exceeding the
nominal Type I error rate, no test can be simultaneously
valid and less conservative than it. In fact, any exact test is
minimally conservative in this sense. As such, even con
servatism, which is often used as an argument against ex
act tests (Agresti & Coull, 1998), favors the exact test un
less the parametric test gains an unfair advantage by being
anti-conservative.
For a more extreme example of a comparison
between an anti-conservative parametric test and a conser
vative exact test, consider the 2x2 table {(8,2);(4,6)}. That
is, there are 2/10 successes in the control group, and 6/10
successes in the active group. With a nominal a level of
0.05 one-sided, the actual a levels are 0.0099 for Fisher’s
exact test and 0.0849 for the chi-square test. Because
0.0849 is closer to 0.05 than 0.0099 is, some would argue
that the chi-square test at the 0.0849 level is most appro
priate. In fact, it may or may not be more appropriate than
Fisher’s exact test at the 0.0099 level, but these are not the
only options. If the response variable is observed fairly
soon after randomization, then one could consider an adap
tive procedure in which recruitment to the study stops only
when the conservatism is small enough. This might be
judged to be the case if either the observed p-value inter
val (Berger, 2001) is entirely on one side of a or the pvalue interval that contains a is itself contained in a fairly
tight pre-defined interval around a . So a larger sample
size might resolve this problem satisfactorily. But even
without resorting to larger sample sizes, it is also clear that
if the chi-square test can be run at an actual 0.0849 level,
then 0.0849 is an attainable p-value, meaning that there is
an outcome for which 8.49% of the outcomes are as or
more extreme. This means that Fisher’s exact test can also
be conducted at the 0.0849 level.
So now there are two issues. First, is it accept
able to use a test with an actual a -level larger than the
planned 0.05? Second, if the answer to the first question
is yes, then which test should be used at the 0.0849 level?
Berger (2000b) noted the inappropriate willingness of some
researchers to accept the general conservatism of exact
tests, without considering the extent of conservatism of
the exact test in question, as sufficient reason to answer
yes to the first question. Yet the extent of conservatism of
any exact test may be quantified by the p-value interval
(Berger, 2001). Furthermore, conservatism is not a prob
lem, because the lower the Type I error rate the better. The
attendant loss of power may be a problem, so the power
needs to be considered.
In any event, if the answer to the first question is
no, then clearly Fisher’s exact test must be used at the
0.0099 level. Regarding the second question, we note that
with a nominal a -level of 0.0849 both the Fisher and
chi-square p-values would be significant exactly 8.49% of

the time. There is still an important distinction, however,
in that no more than 5% of the time would the Fisher pvalue be significant at the 0.05 level. This is not the case,
however, for the chi-square test, for which the p-value
would be significant at the 0.05 level 8.49% of the time. If
events that should occur with probability one in a thou
sand “do not occur with this frequency, there is something
seriously wrong with our understanding of probability”
(Bailar, 1976). Likewise, if the 5thpercentile of a distribu
tion is actually exceeded by 8.49% of the outcomes, then
it is not really the 5thpercentile of the distribution. If the
nominal a level is planned to be 0.05, then it might be
reasonable in some cases to use an actual a level that
exceeds it, perhaps 0.0849. To do so, and then after the
fact report 0.05 as the a level used, is tantamount to plan
ning a study with 200 patients, actually recruiting only 180
patients, yet still reporting the actual sample size as 200.
Because parametric tests are guilty of this type of decep
tion, conservatism cannot justify their use in practice.
The Parametric t-test vs the Wilcoxon-Mann-Whitney
(WMW) Test
In this section we consider the merits of the WMW
test relative to the parametric t-test for unadjusted betweengroup comparisons on the basis of continuous data. We
first point out that there are numerous versions of the WMW
test (Bergmann, Ludbrook, & Spooren, 2000), and this is
likely what prompted Ludbrook (1996) to support exact
tests in general yet specifically criticize the WMW test. In
any event, it is the exact version of the WMW test that we
consider. Williams et al. (2000a) used the WMW test (the
exact version, we assume) to assess resource use and costs
in a RCT comparing open access to routine appointments
for inflammatory bowel disease.
Barber and Thompson (2000) commented that:
1) “resource use and cost data tend to have highly skewed
distributions”,
2) “t-test methods are only strictly valid for data that are
normally distributed”,
3) “the most appropriate simple method for comparing
mean costs is the ordinary t-test”,
4) “use of inappropriate methods for the analysis of cost
data is all too common”.
It is certainly true that many distributions are highly skewed,
and even bell-shaped distributions need not be normally
distributed. Furthermore, even if a variable has a normal
distribution in the target population of interest, allowing
for non-random sampling from this normal distribution
allows for the possibility of accepting or rejecting an ob
servation on the basis of the observation itself. Using the
rejection method (Hoaglin, 1983) would then allow for the
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retained observations to have any distribution we want them
to have. Hence, a lack of random sampling necessarily
precludes the possibility of asserting normality of the sam
pling distribution of the data. If random allocation was
used, then it is the only part of the study that was “experi
mental” (manipulated), and the sampling distribution is a
permutation distribution. This permutation distribution
may converge to normality as the sample size grows infi
nitely large, but we feel safe in agreeing with Geary (1947)
and Hunter and May (1993) that no data (based on a finite
sample size) have a normal distribution. So, we agree with
Barber and Thompson’s (2000) first point.
The second point has an ambiguity owing to the
improper placement of the word “only” in the sentence. In
light of the third point, it is conceivable that “only” was
meant to start the sentence and limit the class of valid analy
ses to the t-test. However, given the context in which this
sentence appears, it seems more likely that “only” was
meant to follow “valid” so as to limit the situations in which
the t-test is valid to those in which the data are normally
distributed. If this latter interpretation is the correct one,
then we agree with the second point. In fact, the perceived
robustness to non-normality of parametric methods (as will
be discussed) is somewhat of an illusion (Hunter & May,
1993).
We develop our comments on the third point by
first noting that Thompson and Barber (2000) claimed that
“only the t-test on untransformed data can be appropriate
for costs, since it is the only one that addresses a compari
son of arithmetic means”. Even conceding the point that it
is reasonable to compare mean costs, we can still disagree
with the third point, which may be interpreted broadly to
include the exact t-test, although the use of the word “ordi
nary” makes it is more plausible that only the parametric ttest was intended. As articulated above, parametric tests
(including the t-test) fail to preserve the Type I error rate
in RCTs. As such, we cannot agree with the third point if it
is interpreted the plausible way. In considering the more
favorable interpretation of the third point, we note that our
desire to maximize power to detect mean differences might
suggest that the exact t-test would be ideal. However, mean
differences may well be accompanied by differences in
spread and/or shape (Hart, 2001), and the nature of these
differences will affect which test is most powerful. In fact,
one could construct an exact test using any test statistic,
including the between-group mean difference in raw costs
(the exact t-test), in ranks (the WMW test), or in Van der
Waerden normal scores. Often the WMW test is more
powerful and/or more robust than the t-test (Lachenbruch,
1992; Higgins & Blair, 2000; Weinberg and Lagakos,
2001), so we cannot agree with the third point of Barber
and Thompson (2000) even if it is interpreted to include
the exact t-test.
Regarding the fourth point, we note that only an
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exact test can protect against a Type I error attributable to
assuming normality. Using an exact test based on a test
statistic that is broadly powerful to detect mean differences,
and getting a low p-value, Williams et al. (2000a) con
vincingly demonstrated that “open access greatly reduces
secondary care costs” (Williams et al., 2000b). Barber
and Thompson (2000) demonstrated that for this data set,
either the normality assumption was sufficiently flawed or
the difference in means was sufficiently accompanied by
shifts in shape and/or scale that the t-test failed to detect
this difference. Apparently, Barber & Thompson (2000)
failed to recognize that their primary contribution is the
demonstration of the truth of the fourth point, which they
accomplished by illustrating that the frequently used para
metric t-test can be quite misleading (Williams et al.,
2000b), and is therefore inappropriate.
The Chi-squared Test vs Fisher’s Exact Test
In a recent study of the effect of neuromuscular
training (Hewett et al., 1999), the chi-square test was used
to analyze knee injuries in female athletes. Clancy (2000)
commented that “Because the observed and expected num
ber of knee injuries was less than five in at least one cell,
an approximate method is inappropriate. An appropriate
method in this instance would have been a Fisher’s exact
test. Incidentally, use of this exact method demonstrated
no statistical significance ..., suggesting that the extreme
variability present in the small sample resulted in an incor
rect finding when an approximate method was used. This
provides all sports medicine researchers with a potent ex
ample of why appropriate statistical analysis is extremely
important.” We comment below on choosing tests based
on expected cell counts. For now, note that Fisher’s exact
test is a misnomer, because as discussed above it is not
exact unless there is random allocation that has as its only
restriction that the treatment totals are fixed at their ob
served values (Berger, 2000a, Section 3.1). As the Hewett
et al. (1999) study appears to have been nonrandomized,
neither Fisher’s exact test nor the chi-square test is exact
in this context. Yet, in response Hewett et al. (2000) ap
peared to accept that Fisher’s exact test was in fact exact,
responding only that:
“the chi-square test is unconditional in that a sig
nificance probability produced by it refers to the
long-term likelihood in repeated experiments of
observing an outcome more extreme than ours,
regardless of the marginal cell counts in these
future experiments under the null hypothesis
(more applicable and inclusive to future stud
ies). Fisher’s exact test, on the contrary, is con
ditional and is, technically, only applicable to
future experiments like ours in which the
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marginal cell counts are fixed at the exact values
that we obtained in our particular study. The sig
nificance probability of the Fisher’s exact test is
much more limited in scope than a chi-square
probability, which is one of the reasons Fisher’s
exact test is rarely used by statisticians.”
Hence, it is reasonable to assume that the same
discussion would have ensued had the study actually been
a RCT. A similar set of views was expressed over ten years
ago by Shuster (1990, p. 26), who stated that Fisher’s ex
act test “is not a true p-value, since the additional proviso
is made that in the replication of the experiment, you must
match the total number of successes with that observed”.
The RCT design is well summarized by Kempthome (1979)
as Origin III sampling, for which valid probability state
ments about what might have happened with different
samples are not supported (Berger, 2000a, Section 2.2).
Applying a parametric test cannot extend the scope to which
valid inferences apply, but producing the appearance of
such extension can be dangerously seductive. Condition
ing on the observed marginal totals, as Fisher’s exact test
does, is required for exactness and validity, and hence is
not a weakness (Berger, 2000a, Section 4.3). In fact, by
providing internal validity (exactness) through recogniz
ing the limitations of the study design, Fisher’s exact test
can actually enhance, and not compromise, the possibility
for external validity Berger (2000a, Section 5). As such,
we find that while the chi-square test may have asymptoti
cally good properties in the random sampling context, its
use in RCTs reflects familiarity, and not appropriateness.
So Why Do Researchers Use Parametric Analyses?
In the Introduction we allowed for the possibility
that one could argue convincingly that a given parametric
test might be preferred to the best available permutation
test provided that it were more robust in preserving the
nominal Type I error rate on the indifference region and
the strong null region. However, simply stating that para
metric tests are robust, without comparing the robustness
of a particular parametric test to that of a competing exact
test, cannot be convincing. When such a comparison is
not offered, and we have never seen one in practice, ro
bustness cannot be offered as a reason to use a parametric
test.
We demonstrated above that conservatism of ex
act tests is not a valid reason to select a parametric test
either. Another reason that is often cited, especially if a
preliminary test of the assumptions underlying the validity
of the parametric test is conducted, is the frequent agree
ment of the exact and parametric tests. The lack of obvi
ous problems resulting from all these years of using para
metric tests has also been cited. One reason for using
parametric tests that is not often cited, but maybe deduced

from the lack of attention dedicated to this issue, is that
some may feel that this is a fourth decimal point issue that
is not ready for prime time. We find no merit in any of
these reasons. In the remainder of this section we provide
journal editors and regulatory authorities with responses
they can use if and when they encounter such arguments.
If credibility for the parametric test derives from
assurances that its p-value will likely be close to the corre
sponding exact one, then this is tantamount to an admis
sion that the exact test is the gold standard (or, perhaps,
the platinum standard). Approximate tests cannot be any
more exact than the exact tests they are trying to approxi
mate and, as approximations to the exact tests, are correct
only to the extent that they agree with the exact test. A
“heads I win, tails you lose” situation then arises, because
if the parametric and exact tests lead to essentially the same
inference, then this is as much an argument in favor of the
exact test as it is for the parametric test, and there is no
benefit to using the parametric test. If they do not agree,
then the exact test needs to be used.
Feinstein (1993) wrote that “a statistician defend
ing the general use of t and chi-square tests in modem re
search could point to their frequent accuracy. With the
same argument, an old school clinician might point out
that diabetes mellitus can usually be diagnosed by tasting
the urine or applying Benedict’s reagent. With the avail
ability of better and equally easy ways to diagnose diabe
tes, however, these old procedures were gradually replaced
by techniques that are more reliable. Similarly, when the
aid of computers allows permutation or randomization tests
to be performed easily, the t-test and chi-square test will
probably begin to disappear as routine procedures. Even
without computers, however, the permutation tests are the
preferable and perhaps mandatory procedures to be used”.
Even in those cases in which the two tests agree perfectly,
Altman (1982, p. 67) makes a compelling case that setting
a precedent for poor methodology encourages other re
searchers to use the same poor methodology in the future.
It is likely that in some of these future studies the results
will be materially affected.
For these reasons, we believe that even if para
metric tests tend to agree with exact tests, meaning that
with “high” (left undefined) probability, the parametric pvalue will be “close” (also left undefined) to the exact pvalue, they still should not be used. Even with preliminary
tests of the assumptions, the general similarity of the two
tests does not exclude the possibility of discordant results
between the tests for given data sets. This is because the
preliminary test has as its null hypothesis the conditions
that would allow for the use of the parametric test. The
null hypothesis cannot be proven by a formal test of hy
pothesis, especially when the test suffers from poor power,
as the preliminary tests to detect conditions that would ren
der the parametric test unreliable (such as non-normality)
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especially to regulators and medical journal editors, who,
For example, Little (1989) presented a 2x2 table, given their “public duty to ensure that reports of research
with cell counts {(170,2);( 162,9)}. Because each expected provide valid information” (WAME, 2001), might be seen
cell count is at least 5, the chi-square test would be used, as functioning as de facto regulators. Given that papers
yet for one-sided testing (which is generally conducted at with poor methodology can cause harm (in numerous ways)
the 0.025 level) the chi-square test would find significance and cannot be “unpublished” (Altman, 1982), consumers
(p=0.0162) and Fisher’s exact test would not (p=0.0299). of medical publications (including practicing physicians
Barber and Thompson (2000), Berger (2000a, Section 2.3), and HMOs) should hold these publications to rigid stan
and Clancy (2000) presented other real data examples in dards before accepting and acting on the results (by alter
which use of the parametric test matters more than in the ing reimbursement or prescribing patterns). That is, “be
fourth decimal. Given the danger in restricting the use of cause low p-values are not themselves persuasive but re
exact analyses to cases in which the need for such use is quire solid methodology as a foundation, we must resist
obvious, the prudent approach is to be suspicious of as the pressure to view data positively that were produced
sumptions even when there is no apparent reason to be from poor methodology” (Moye, 1999). Patients might
suspicious. The only way to validate a particular paramet want to ask their physicians about the evidence on which a
ric p-value, and ensure that it differs from the correspond decision is based. Given the importance of analyzing RCT
ing exact p-value in only the fourth decimal place, is to data with methods that are applicable to and appropriate
compare it to the exact p-value. If the exact p-value needs for RCTs, medical schools might consider offering degrees
to be computed to validate the approximate one, then why specifically in RCT design and analysis. Granting institu
not simply use the exact one, the ready availability of which tions might want to ensure that medical research is sup
renders the extent to which an approximate test approxi ported by a reality-based trialist who will build robustness
into the analyses by making a minimum of unverifiable
mates it irrelevant (Berger, 2000a)?
As for the precedent for using parametric analy assumptions.
Because those who claim to be methodological
ses without obvious damage, we note that p-values pro
vided by inappropriate methodology are numbers between experts often disagree among themselves, there is both
zero and one, and look just like p-values produced by ap conflicting information and misinformation being taught
propriate methodology. Alarms do not go off when an in in schools and published in both the medical and the sta
appropriate method is used. In fact, two forces conspire to tistical literature. Two steps might put medical research
conceal the damage caused by the use of inappropriate ers in a better position to evaluate the analyses a statisti
methodology by separating the manifestation of this dam cian proposes. First, medical researchers could think hard
age from the antecedent usage of the inappropriate meth about how best to analyze the data, possibly reading
odology. Specifically, when inappropriate methodology Feinstein (1993) carefully if the study is a RCT. Second,
causes damage, there is both a diffusion of the damage to a the medical researcher could require the statistician to jus
set of patients who do not act or think as a unified indi tify the proposed analyses with logic and reason, instead
vidual and a lag time in the manifestation of this damage. of (or in addition to) references. It would help if the stat
Add to this that the patients may be sick anyway, and there istician would provide an informed consent document to
is little hope of ever tracing the damage back to the cause. spell out the assumptions and limitations of the proposed
That damage actually does occur as the result of medical analyses. See the Appendix for an example dealing with
errors, and often goes unnoticed, has been well documented parametric analyses. Although it is unlikely that statisti
(Moore, 1995). How much easier would the life of an cians who use parametric analyses would make themselves
epidemiologist be if every risk were easily identified and look bad by providing such a document, the medical re
linked to the damage it caused? In fact there have always searcher could bring some version of this document to the
been real risks that were not mitigated by our ignorance of attention of the statistician to initiate the discussion about
their existence. The lack of an identifiable victim com the analyses planned.
plaining about the use of parametric tests cannot be inter
Developers of statistical software and authors of
preted as the lack of a victim.
text books should offer analyses with a minimum of re
quired assumptions and should make explicit the assump
Conclusion
tions and limitations of all analyses. This presently is not
the case (Bergmann, Ludbrook, & Spooren, 2000). Real
It has been said that for evil to prevail all it takes is a few ity-based trialists should, when confronting a researcher
good people to stand by and do nothing. The same could endorsing a parametric analysis, consider the advise of
be said for the “scandal of poor medical research” (Altman, Bross (1990), who wrote that “if we politely call a method
1994). To avoid being part of the problem, all involved ‘dubious’, the criticism can be brushed off as a ‘difference
parties should insist on quality methodology. This applies of opinion between experts’. However, if most
often do.
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statisticians call a method ‘fraudulent’, the criticism can
not be brushed off so easily.”. Hopefully this article will
prove useful to reality-based trialists in their efforts to ar
gue effectively against parametric analyses, or at least us
ing parametric analyses without carefully checking their
situation-specific robustness.
As for the researcher who wants to resist realitybased analyses, and maintain the status quo of routinely
using parametric tests, we agree with Bross (1990) that
“the user of a statistical method has the responsibility for
dealing with the scientific question: Are the assumptions
valid? In particular, when human health and safety might
be jeopardized ..., a statistician has a direct responsibility
to protect the public health and safety by following fail
safe principles in dealing with any assumptions”. Given
the logical basis for reality-based analyses, it is likely only
a matter of time before the medical profession catches on
that the normal theory that perplexed them in medical
school actually has little or no place in RCTs. When this
happens, and proper analyses become the rule instead of
the exception, the emperor’s new clothes will be seen for
what they are, and some may well wonder why the naked
emperor was allowed to rule for so long. We would not
want to be in a position of having to explain why right up
until the time that we were forced to cease and desist we
continued to use inappropriate methods that resulted in
medical errors leading to unnecessary morbidity and mor
tality. Although much work remains to fully elucidate the
optimal methods for comparing medical interventions, and
while there may never be a bias-proof system, there can be
no excuse for not getting the easy ones right.
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Appendix
Sample Informed Consent Document for Statisticians to
Provide to Medical Researchers (or Vice Versa)
By signing this form you agree that you have been
informed of the following. In trusting me with your data,
you recognize that I might perform analyses that are tech
nically correct only if various conditions are true. The
reality is that these conditions could not possibly be true.
Yet in basing the analyses on the truth of these conditions
we can follow the tradition of using such parametric analy
ses. It is unlikely that the results we obtain will differ very
much from those we would have obtained had we used
exact methods, which are readily available. In fact, it would
not be difficult for me to compare the approximate results
to the exact results, but I will not do so, because, as stated,
it is unlikely that they will differ by very much. This means
that there is the possibility that the parametric results will
differ sufficiently from the exact results to lead to different
conclusions. These conclusions may then be inappropri
ate, but this would not be discovered right away, because I
will not compute the exact results. In the event that in the
future it is revealed that damage resulted from the use of
improper statistical methods, you agree to indemnify me.

